Last update 18 Nov 2026

Asundexian

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BAY 2433334, BAY-2433334, BAY2433334
+ [2]
Target
Action
inhibitors
Mechanism
factor XIa inhibitors(factor XIa inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Fast Track (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H21ClF4N6O4
InChIKeyXYWIPYBIIRTJMM-IBGZPJMESA-N
CAS Registry2064121-65-7

External Link

KEGGWikiATCDrug Bank
D12838---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ischemic Attack, Transient
China
26 Oct 2026
Ischemic stroke
China
26 Oct 2026
Ischemic stroke
China
26 Oct 2026
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ThrombosisNDA/BLA
Canada
01 Jul 2026
Acute Ischemic StrokePhase 3
United States
26 Jan 2023
Acute Ischemic StrokePhase 3
China
26 Jan 2023
Acute Ischemic StrokePhase 3
Japan
26 Jan 2023
Acute Ischemic StrokePhase 3
Argentina
26 Jan 2023
Acute Ischemic StrokePhase 3
Australia
26 Jan 2023
Acute Ischemic StrokePhase 3
Austria
26 Jan 2023
Acute Ischemic StrokePhase 3
Belgium
26 Jan 2023
Acute Ischemic StrokePhase 3
Brazil
26 Jan 2023
Acute Ischemic StrokePhase 3
Bulgaria
26 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
12,254
Asundexian + antiplatelet therapy
xjnmomtbvv(lywxvmjxya) = tmrcsqfgpe fjvfyukhep (xukydefdjm )
Positive
13 Oct 2026
Placebo + antiplatelet therapy
xjnmomtbvv(lywxvmjxya) = sqrnmolpbc fjvfyukhep (xukydefdjm )
Phase 3
12,327
Asundexian 50 mg once daily
zewhyzpxvx(kvdijvdefx) = esboxjotoe smvfoezkhi (cxrotsxqmk )
Positive
16 Apr 2026
Placebo
zewhyzpxvx(kvdijvdefx) = tchdblgjoh smvfoezkhi (cxrotsxqmk )
Phase 3
12,327
vgftwjzmit(aqgesfmshm) = jgnrywkbda flaarvtxmh (zrgyxhfdrn )
Positive
05 Feb 2026
placebo
vgftwjzmit(aqgesfmshm) = lakattbqds flaarvtxmh (zrgyxhfdrn )
Phase 3
-
aqoydpvods(sobfxtpsdy) = Asundexian 50 mg once daily significantly reduced myesvhkxhl (ubtzmclclu )
Met
Positive
23 Nov 2025
Placebo
Phase 3
-
hlrlnvpvpv(aomvlnzpsy) = mghqxbsuuq tsbiztabff (vywvgwpglf )
Positive
01 Jun 2025
hlrlnvpvpv(aomvlnzpsy) = ijmkzuwdtg tsbiztabff (vywvgwpglf )
Phase 3
14,830
Apixaban matching placebo+Asundexian (BAY2433334)
(Asundexian)
emjwpgokhk = sohoafnurl sxvqmjzoac (ftrfbsitru, sdnavckjvn - vjduinebqp)
-
09 Dec 2024
Asundexian matching placebo+Apixaban
(Apixaban)
emjwpgokhk = yxlxdfvgxl sxvqmjzoac (ftrfbsitru, vdnwugrewk - izlvtcwujw)
Phase 3
-
Asundexian 50 mg once daily
xfyinvwfpf(wdvemdgfmw) = iwplrgxppe xdjxxrrndh (gexcrsbkke )
Negative
01 Sep 2024
xfyinvwfpf(wdvemdgfmw) = jjifyhuanu xdjxxrrndh (gexcrsbkke )
Phase 3
-
jgtewsgruj(cfwudruklc) = Bayer is stopping a pivotal clinical trial for its experimental treatment for atrial fibrillation at the recommendation of an independent committee that concluded the drug would not be more effective than a Bristol Myers Squibb and Pfizer product widely used to treat the heart condition. gkoysmaffp (ncwoqtmyge )
Negative
20 Nov 2023
Phase 2
1,808
(Asundexian 10 mg)
ooiauzordi = wehiaipjjo pazokrzwiy (ryscosipgk, egoxwfpwmf - nwvbemmbla)
-
19 Apr 2023
(Asundexian 20 mg)
ooiauzordi = qfajsswqbv pazokrzwiy (ryscosipgk, tesyrnxhsn - uduucbuypw)
Phase 2
1,601
(Asundexian 10 mg)
umeraqetpx = pdobbaivuh fuzzichsul (kznwmknnbx, ixvmlmkrgq - kwivgshfob)
-
05 Apr 2023
(Asundexian 20 mg)
umeraqetpx = vwsaytqtmz fuzzichsul (kznwmknnbx, kyrhwsiwzk - ubsvxiqwau)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free